Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
CAR-T
Biotech
Regeneron does 180 on 2seventy lymphoma CAR-T
Regeneron has given up on a CAR-T candidate acquired from 2seventybio last year, before it finished a phase 1/2 lymphoma study.
James Waldron
Oct 23, 2025 10:57am
Kite puts $1.64B on the line for Pregene's in vivo CAR-Ts
Oct 16, 2025 4:56pm
Cabaletta's CAR-T wipes out B cells with no preconditioning
Oct 10, 2025 11:11am
BMS inks $1.5B deal to pull Orbital into its sphere of influence
Oct 10, 2025 8:45am
ARPA-H goes all in on in vivo cell therapy
Oct 8, 2025 4:04pm
ARPA-H invests in Kernal's mRNA cell therapy
Oct 7, 2025 3:20pm
